Journals / MN Kardiyoloji / 2013 / Cilt: 20 - Sayı: 1

Pulmonary hypertension diagnosis and treatment

Pulmoner hipertansiyon tanı ve tedavisi

Pages
41–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper we discussed the diagnosis and treatment of pulmonary hypertension with current guidelines.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pulmonary hypertension has many etiological reasons and it is a progressive and insidious disease regardless of the underlying cause.
📊
Key Findings & Data:The next step after the diagnosis of PAH is to determine the severity of the disease. 4 year survival of World Health Organization (WHO) fonksional class (FC) 1 or 2 without treatment is less than 50% 2 year survival of WHO FC 3 or 4 patient is less than 60% Patients with even minor symptoms without treatment get worsen progressively.
💡
Conclusion & Impact:In this paper we discussed the diagnosis and treatment of pulmonary hypertension with current guidelines.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pulmonary hypertension has many etiological reasons and it is a progressive and insidious disease regardless of the underlying cause. The diagnosis of PH is generally delayed to advanced stages as it does not have pathagonomic symptoms and signs. The response of PH to the treatment is less and the prognosis is poor at advanced stages so early diagnosis and treatment is important. The next step after the diagnosis of PAH is to determine the severity of the disease. 4 year survival of World Health Organization (WHO) fonksional class (FC) 1 or 2 without treatment is less than 50% 2 year survival of WHO FC 3 or 4 patient is less than 60% Patients with even minor symptoms without treatment get worsen progressively. The aim of pulmonary arterial hypertension (PAH) treatment is to decrease the severity of PAH, to increase life quality, functional capacity and right ventricul functions, and to prevent possible thromboembolic events. In this paper we discussed the diagnosis and treatment of pulmonary hypertension with current guidelines.

Özet

Pulmoner hipertansiyonun (PH) etyolojik olarak birçok sebebi mevcut olup, sebebi ne olursa olsun ilerleyici ve sinsi bir hastalıktır. PH’nın kendine özgü semptomlarının olmamasından dolayı tanı konulması gecikmekte ve ileri evrelerde tanı konmaktadır. PH ileri ev- relerde tedaviye daha az yanıt vermesi ve prognozunun kötü olması sebebiyle erken tanı ve tedavisi önem arz etmektedir Pulmoner hipertansiyon tanısı konulduktan sonraki basamak, hastanın kliniğinin ağırlık derecesinin belirlenmesidir. Dünya Sağlık Örgütü (DSÖ) FS I veya II hastalarda tedavi edilmediğinde 4 yıllık sağkalım %50’nin altındadır. DSÖ fonksiyonel sınıflar (FS) III veya IV hastalarda ise 2 yıllık sağkalım %60’ın altındadır. Hafif semptomatik hastalarda bile, PH tedavi edilmediğinde hızla kötüleşmektedir. Pulmoner hipertansiyon tedavisinde amaç; PH şiddetini azaltmak, fonksiyonel kapasitesini, yaşam kalitesini düzeltmek, sağ ventrikül işlevlerini iyileştirmek, oluşabilecek tromboembolik yükü azaltmak ve iyi prognoz sağlamaktır. Bu yazıda güncel kılavuzlar ışığında pulmoner hipertansiyon tanı ve tedavisi anlatılmıştır.

🔖

Cite This Article

YILDIRIM, O., AKILLI, H., GÖK, H. (2013). Pulmonary hypertension diagnosis and treatment. MN Kardiyoloji, Cilt: 20 - Sayı: 1, 41–48. https://ajindex.com/articles/297895

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Gali N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
  2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23 3. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Resp Crit Care Med 2009;179:615-21 4. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multide-tector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48:680-4 5. Dartevelle P, Fadel E, Mussot S, et al. Chronic throm- boembolic pulmonary hypertension. Eur Respir J 2004; 23:637-48
  3. Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. Eur Heart J 2007;28:1187-9
  4. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546-52
  5. Sitbon O, Humbert M, Jais X, loos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111: 3105-11
  6. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidencebased treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:78 10. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pul-monary hypertension. Circulation 2006;114:1482-9
  7. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? EurHeart J 2009;30:256-65
  8. Bendayan D, Hod M, Oron G, et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet Gynecol 2005;106:1206-10
  9. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-7 14. Kawut SM, Horn EM, Bereka